Can OHR Pharmaceutical Inc (OHRP)’s Run Continue?

Judging by the fact that OHR Pharmaceutical Inc (NASDAQ:OHRP) has witnessed a declination in interest from the entirety of the hedge funds we track, logic holds that there exists a select few money managers that elected to cut their entire stakes in the third quarter. At the top of the heap, Kevin Kotler’s Broadfin Capital sold off the biggest stake of the 700 funds watched by Insider Monkey, valued at close to $4.5 million in stock. Hal Mintz’s fund, Sabby Capital, also dumped its stock, about $0.2 million worth. These bearish behaviors are interesting, as aggregate hedge fund interest was cut by 4 funds in the third quarter.

Let’s now take a look at hedge fund activity in other stocks similar to OHR Pharmaceutical Inc (NASDAQ:OHRP). These stocks are Demand Media Inc (NYSE:DMD), Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), Caladrius Biosciences Inc (NASDAQ:CLBS), and Dawson Geophysical Company (NASDAQ:DWSN). This group of stocks’ market caps are closest to OHRP’s market cap.

As you can see these stocks had an average of 7 hedge funds with bullish positions and the average amount invested in these stocks was $11 million. That figure was $2 million in OHR Pharmaceutical Inc (NASDAQ:OHRP)’s case. Demand Media Inc (NYSE:DMD) is the most popular stock in this table. On the other hand Caladrius Biosciences Inc (NASDAQ:CLBS) is the least popular one with only 5 bullish hedge fund positions. OHR Pharmaceutical Inc (NASDAQ:OHRP) is not the least popular stock in this group but hedge fund interest is still below average. This is a slightly negative signal and we’d rather spend our time researching stocks that hedge funds are showing confidence in. Given that it’s already crashed once this year and it’s pipeline doesn’t look any stronger, we believe there are better options in the micro-cap biopharma space.